Oncology
Study maps self-reinforcing SRSF1–AURKA–MYC circuit in pancreatic cancer cells
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
Researchers at Cold Spring Harbor Laboratory report they have identified a three-part molecular circuit involving SRSF1, Aurora kinase A (AURKA) and MYC that helps drive aggressive pancreatic ductal adenocarcinoma. In laboratory models, a splice-switching antisense oligonucleotide designed to alter AURKA splicing disrupted the circuit, reducing tumor-cell viability and triggering programmed cell death.
An alliance between Clínica Medilaser and the Instituto Médico Oncológico has consolidated an integrated program to treat central nervous system tumors in southern Colombia. The service, led by neurosurgeon Silvia Quintero, serves patients from several regions from its Neiva site.
AI에 의해 보고됨
One month after the nationwide oncology sanitary alert took effect, Health Minister May Chomali led the signing of a decree transferring $154 billion from the Ministry of Hacienda to the Ministry of Health (Minsal). The funds will exclusively support the Oncology Alert Plan, enhancing public health services' capacity to resolve oncology waiting lists affecting thousands of patients.
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.
AI에 의해 보고됨
Oncologist Paulo Hoff warned that excessive sun exposure is the most common cause of cancer, particularly non-melanoma skin cancer. In a course on CasaFolha, he emphasizes the importance of prevention and early diagnosis to boost cure rates. Hoff recommends avoiding the sun between 10am and 2pm and using sunscreen.
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
AI에 의해 보고됨
Researchers at Spain's National Cancer Research Centre (CNIO) have developed a comprehensive catalog of mutational 'scars' in DNA caused by cancer. This breakthrough, published in Nature, could help bypass resistances to treatments like PARP inhibitors. The study analyzes thousands of tumor samples to identify key genetic patterns.
Sonora activates cancer-fighting linear accelerator and announces four hospital projects
2026년 03월 10일 18시 13분Roche shares decline after giredestrant trial fails endpoint
2026년 02월 19일 03시 55분Stf approves agreement for funding oncology treatments in Sus
2026년 02월 18일 04시 47분Egypt and Canada deepen healthcare cooperation focusing on digital health and oncology
2026년 02월 13일 17시 37분Cuba battles cancer amid shortages
2025년 11월 20일 14시 53분Weill Cornell team identifies CD47–TSP-1 signal behind T cell exhaustion; blocking it revives anti-tumor immunity in mice
2025년 11월 02일 03시 05분Clínica Medilaser leads blood cancer diagnosis and treatment
2025년 10월 30일 14시 26분Eastern Cape chemotherapy shortages risk pediatric patients
2025년 10월 22일 07시 57분Drug combination slows progression of aggressive prostate cancer
2025년 10월 20일 00시 43분Study confirms rise in cancer cases among adults under 50